drugset / Trial / NCT06769659

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

NCT06769659 ↗

Phase 2 Recruiting 12 enrolled NeuroPro Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.

Timeline

Start
2025-03-11
Primary completion
2026-08-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator NPT 2042 Unknown 80 mg Oral
Comparator NPT 2042 Unknown 160 mg Oral